Clinical Trial

Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas

Study acronym: CIME
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
CIME is a multicenter, randomised, comparative, open-label phase III study aiming to compare the survival of patients suffering from MSI-H/dMMR locally advanced or metastatic oeasogastric adenocarcinoma treated by a bi-immunotherapy (experimental arm) versus standard current treatment (FOLFOX/XELOX + nivolumab : standard arm).
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2024-03-28; most recent amendment 2026-06-23.
Status change: Not Yet Recruiting → Recruiting 2025-12-08
Trial Details
NCT Number NCT06346197
Lead Sponsor Centre Leon Berard
Collaborators: Agenus Inc.
Conditions Gastric Cancer, MSI-H, Metastatic Cancer, Advanced Cancer
Enrollment 132 participants
Start Date 2025-12-08
Primary Completion 2028-05-15 (estimated)
Study Completion 2028-05-15 (estimated)
Updated on ClinicalTrials.gov 2026-06-25